期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

遗传性乳腺癌-卵巢癌综合征中BRCA1/2的表达 被引量：1

The expression of BRCA1/2 in patients with hereditary breast and ovarian cancer syndrome
原文传递
导出
摘要 目的检测BRCA1/2在遗传性乳腺癌-卵巢癌综合征(HBOC)患者所患卵巢癌和散发性卵巢癌组织中蛋白表达的差异,探讨其在HBOC患者卵巢癌发病中的意义。方法收集我院妇科2001年1月至2010年10月HBOC患者卵巢癌40例和散发性卵巢癌20例(对照组)的石蜡组织标本,行免疫组化检测BRCA蛋白的表达;收集2011年1月-2013年12月HBOC卵巢癌11例和同期散发性卵巢癌10例(对照组)的新鲜标本,行Western Blot检测BRCA蛋白的表达。结果免疫组化结果显示HBOC组BRCA2蛋白阳性产物OD值(0.64±0.013)明显高于对照组(0.24±0.002,<0.05)。Western blot结果显示HBOC组BRCA2蛋白OD值(0.68±0.02)明显高于对照组(0.26±0.01,<0.05)。但是,对于BRCA1没有明显区别。结论 BRCA2蛋白在HBOC患者卵巢癌组织过表达提示BRCA2可能与HBOC的发病相关。 Objective To study the expression of BRCA1/2 in ovarian cancers and sporadic ovarian cancers of patients with hereditary breast and ovarian cancer syndrome（HBOC）. Methods The BRCA1/2 expressions in ovarian cancers and sporadic ovarian cancers（controls） of HBOC were detected by immunohistochemistry and Western blot, and analyzed statistically. Results Both of immunohistochemistry and Western blot analysis showed that the positive expression level of BRCA2 was significantly higher in HBOC ovarian cancers than in the control group（P〈0.05）, but with no obvious difference for BRCA1. Conclusion The overexpression of BRCA2 in HBOC ovarian cancers indicates that BRCA2 might be related to the pathogenesis of HBOC.
作者 李天人 畅华 郭科军
机构地区 中国医科大学附属第一医院妇科
出处 《解剖科学进展》 CAS 2014年第3期233-236,共4页 Progress of Anatomical Sciences
关键词 卵巢肿瘤 遗传性乳腺癌一卵巢癌综合征 BRCA1 BRCA2 Ovarian neoplasms hereditary breast and ovarian cancer syndrome BRCA1 BRCA2
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Antonion A, Pbaroah PD, Nu'od S, eta. Average risks of breast and ovarian eaneer associated with BRCA1 or BRCA2 mutations detected in ease series unseleeted for family histor/: A combined analysis of 22 studies[J]. Am J Hum Genet, 2003, 72: 1 117-1130.
  • 2Boyd J. Hereditary ovarian cancer: What we know[J]. Gynecol Oneol, 2003, 88: 58-S10.
  • 3Gallagher DJ, Konner JA, Bell--MeCuinn KM. Survival in epithelial ovarian eancer:a muhivariale analysis incorporating BRCA mutation status andplatinum sensitivity[J]. Ann Oncol. 2011, 22(5): 1127- 1132.
  • 4Miki Y, Swensen J, Shattuck- Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI[J]. Science, 1994, 266(5182): 66-71.
  • 5Tavtigian SV, Simttrd J, Rommens J, et al. The complete BRCA2 gene and mutations in chroalnsome 13q2-1inked kindred'sO]. Nat (Lsnet, 1996, 12(3): 333-337.
  • 6Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation caiTiers[J]. Bri J Cancer, 2007, (01): 11-15.
  • 7Sogaard M, Kjaer SK, Gayther S, el al. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention[J]. Aeta Obstet Cynecol Scand, 2006, 85(1): 93-105.
  • 8Fishman A, Dekel E, Chetrit A, et al. Patients with double primary tumors in the breast and ovary-clinical characteristics and BRCAI- 2 mutations status[J]. Gynecol Oncol, 2000, 79: 74-78.
  • 9吴氢凯,罗来敏,吴洪军,陶雯琪,陆洪芬,施达仁,冯洁.BRCA1蛋白在原发性上皮性卵巢癌中的表达[J].上海交通大学学报（医学版）,2006,26(12):1326-1330. 被引量：2
  • 10Phelan CM, Kwan E, Jack E. A low ffequecy of nonfounder BRCAI mutations in A:shkenazi Jewish breast-ovarian cancer families[J]. Human Mutation, 2002, (05): 352-357.

二级参考文献15

  • 1李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量：74
  • 2Werness BA, Eltabbkh GH. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features [J]. Int J Gynecol Pathol, 2001, 20 (1) : 48-63.
  • 3Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 [J].Science, 1994,266(5182) : 66 -71.
  • 4Wong AS, Auersperg N. Ovarian surface epithelium: family history and early events in ovarian cancer [ J ]. Reprod Biol Endocrinol,2003, 1:70.
  • 5Chen Y, Chen CF, Riley D J, et al. Aberrant subcellular localization of BRCA1 in breast cancer [J]. Science 1995,270 (5237) : 789 - 791.
  • 6Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cells [ J ]. Science, 1996, 272(5258) : 123 - 126.
  • 7Garvin AM, Attenhofer -haner M, Scott RJ. BRCA1 and BRCA2mutation analysis in 86 early onset breast/ovarian cancer patients[J]. J Med Genet, 1997, 34(12): 990 -995.
  • 8Rodriguez JA, Henderson BR. Identification of a functional nuclear export sequence in BRCA1 [J]. J Biol Chem, 2000, 275(49) :38589 - 38596.
  • 9Williams RS, Chasman DI, Hau DD, et al. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations[J]. J Biol Chem, 2003,278(52):53007 -53016.
  • 10Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1 [ J]. N Engl J Med, 1996,335 (19) : 1413 - 1416.

共引文献1

同被引文献23

  • 1Fayyaz S S,Yasunori O,Richard A F.The inflammasome in pathogen recognition and inflammation[J].J Leuk Biol,2007(8):259-264.
  • 2Shi J J,Zhao Y,Wang Y P,et al.Inflammatory caspases are innate immune receptors for intracellular LPS[J].Nature,2014,514:187-192.
  • 3Cui J,Zhu L,Xia X,et al.NLRC5negatively regulates the NF-kappaB and type I interferon signaling pathways[J].Cell,2010,141(3):483-496.
  • 4Neerincx A,Lautz K,Menning M,et al.A role for the human nucleotide-binding domain,leucine-rich repeatcontaining family member NLRC5in antiviral responses[J].J Biol Chem,2010,285(34):26223-26232.
  • 5Davis B K,Roberts R A,Huang M T,et al.Cutting edge:NLRC5-dependent activation of the inflammasome[J].J Immun,2011,186(3):1333-1337.
  • 6Badr C E,Niers J M,Tjon-Kon-Fat L,et al.Real-Time Monitoring of Nuclear Factor kappa B Activity in Cultured Cells and in Animal Models[J].Mol Imag,2009,8(5):278-290.
  • 7Meissner T B,Li A,Biswas A,et al.NLR family member NLRC5is a transcriptional regulator of MHC class I genes[J].Proc Natl Acad Sci USA,2010,107(31):13794-13799.
  • 8Neerincx A,Rodriguez G M,Steimle V,et al.NLRC5controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner[J].J Immunol,2012,188(10):4940-4950.
  • 9Benko S,Magalhaes J G,Philpott D J,et al.NLRC5limits the activation of inflammatory pathways[J].J Immunol,2010,185:1681-1691.
  • 10Li L,Xu T,Huang C,et al.NLRC5Mediates Cytokine Secretion in RAW264.7 Macrophages and Modulated by the JAK2/STAT3 Pathway[J].Inflammation,2014,37:835-847.

引证文献1

二级引证文献2

解剖科学进展
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部